- Home
- BRSP vs IMTX Comparison
BRSP vs IMTX Comparison
Compare BRSP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRSP
- IMTX
- Stock Information
- Founded
- BRSP 2017
- IMTX N/A
- Country
- BRSP United States
- IMTX Germany
- Employees
- BRSP N/A
- IMTX N/A
- Industry
- BRSP Real Estate Investment Trusts
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRSP Real Estate
- IMTX Health Care
- Exchange
- BRSP Nasdaq
- IMTX Nasdaq
- Market Cap
- BRSP 686.2M
- IMTX 579.8M
- IPO Year
- BRSP 2018
- IMTX N/A
- Fundamental
- Price
- BRSP $5.13
- IMTX $5.52
- Analyst Decision
- BRSP Buy
- IMTX Strong Buy
- Analyst Count
- BRSP 4
- IMTX 4
- Target Price
- BRSP $6.83
- IMTX $14.67
- AVG Volume (30 Days)
- BRSP 536.7K
- IMTX 816.9K
- Earning Date
- BRSP 07-29-2025
- IMTX 08-12-2025
- Dividend Yield
- BRSP 12.50%
- IMTX N/A
- EPS Growth
- BRSP N/A
- IMTX N/A
- EPS
- BRSP N/A
- IMTX N/A
- Revenue
- BRSP $340,600,000.00
- IMTX $155,801,989.00
- Revenue This Year
- BRSP N/A
- IMTX N/A
- Revenue Next Year
- BRSP $12.19
- IMTX $1.92
- P/E Ratio
- BRSP N/A
- IMTX N/A
- Revenue Growth
- BRSP N/A
- IMTX 93.56
- 52 Week Low
- BRSP $4.16
- IMTX $3.30
- 52 Week High
- BRSP $6.71
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- BRSP 46.81
- IMTX 49.74
- Support Level
- BRSP $5.01
- IMTX $5.23
- Resistance Level
- BRSP $5.22
- IMTX $5.71
- Average True Range (ATR)
- BRSP 0.11
- IMTX 0.29
- MACD
- BRSP -0.01
- IMTX -0.08
- Stochastic Oscillator
- BRSP 32.88
- IMTX 25.22
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.